Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.37 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.37 |
| ▸ | P2RY2 | P41231 | 5/20 | 0.36 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CDA | P32320 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15850638 | 1.00 | LMNA (0.41) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL19981003 | 1.00 | LMNA (0.41) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL18902462 | 1.00 | LMNA (0.41) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL21970361 | 1.00 | LMNA (0.41) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL24024592 | 1.00 | LMNA (0.41) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL24024770 | 1.00 | LMNA (0.41) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL24024883 | 0.98 | LMNA (0.43) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL24024879 | 0.98 | LMNA (0.43) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL15892158 | 0.94 | P2RY6 (0.37) | P2RY6P2RY14NT5EP2RY2P2RY4 | |
| SCHEMBL17853310 | 0.94 | P2RY6 (0.37) | P2RY6P2RY14NT5EP2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180079768-A1 | METHOD FOR PRODUCING GLYCOSIDE COMPOUNDS | BONAC CORPORATION (JP) | 2018-03-22 | — | — | US | disclosed |
| US-9481702-B2 | Glycoside compound, method for producing thioether, ether, method for producing ether, method for producing glycoside compound, method for producing nucleic acid | BONAC CORPORATION (JP) | 2016-11-01 | — | — | US | disclosed |
| US-20140206856-A1 | GLYCOSIDE COMPOUND, METHOD FOR PRODUCING THIOETHER, ETHER, METHOD FOR PRODUCING ETHER, METHOD FOR PRODUCING GLYCOSIDE COMPOUND, METHOD FOR PRODUCING NUCLEIC ACID | BONAC CORPORATION (JP) | 2014-07-24 | — | — | US | disclosed |
| WO-2013027843-A1 | GLUCOSIDE COMPOUND, METHOD FOR PRODUCING THIOETHER, ETHER, METHOD FOR PRODUCING ETHER, METHOD FOR PRODUCING GLUCOSIDE COMPOUND, METHOD FOR PRODUCING NUCLEIC ACID | 株式会社ボナック (JP) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206856-A1 | GLYCOSIDE COMPOUND, METHOD FOR PRODUCING THIOETHER, ETHER, METHOD FOR PRODUCING ETHER, METHOD FOR PRODUCING GLYCOSIDE COMPOUND, METHOD FOR PRODUCING NUCLEIC ACID | DDOST, TENT4A, TRDMT1 | LMNA 2625/4885THRB 1261/4885MTOR 2507/4885 |
| US-20180079768-A1 | METHOD FOR PRODUCING GLYCOSIDE COMPOUNDS | TST, DIMT1, DERA | LMNA 3184/4885THRB 3329/4885MTOR 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.